Cofttek holdings limited

GPCR&G protein

VU0364770 (61350-00-3)

VU 0364770 is a positive allosteric modulator(PAM) of mGlu4 with EC50 of 1.1 μM, exhibits insignificant activity at 68 other receptors, including other mGlu subtypes.

Not Intended for Therapeutic Use. For research use only.

CAS: 61350-00-3 Category

VU0364770 (61350-00-3) Description:

VU0364770 is a Positive allosteric modulator at mGlu4 receptors (EC50 = 290 nM in mGlu4-expressing HEK 293 cells). VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson’s disease.

VU0364770 (61350-00-3) Specifications:

Product Name VU0364770
Synonyms VU0364770, VU 0364770, VU 0364770
Chemical Names 61350-00-3; VU 0364770; VU0364770; N-(3-chlorophenyl)picolinamide; N-(3-chlorophenyl)-2-pyridinecarboxamide; N-(3-chlorophenyl)pyridine-2-carboxamide
Purity >98%
CAS Number 61350-00-3
Molecular Formula C12H9ClN2O
Molecular Weight 232.667 g/mol
Monoisotopic Mass 232.04 g/mol
InChIKey SUYUTNCKIOLMAJ-UHFFFAOYSA-N
InChi Code InChI=1S/C12H9ClN2O/c13-9-4-3-5-10(8-9)15-12(16)11-6-1-2-7-14-11/h1-8H,(H,15,16)
SMILES O=C(C1=NC=CC=C1)NC2=CC=CC(Cl)=C2
Form Powder
Color white
Solubility  may be formulated in DMSO
Storage Temp.  −20°C
Shelf life >2 years if stored properly.
Handling Dry, dark
Application  a positive allosteric modulator(PAM) of mGlu4

 


=

RIDADR NONH for all modes of transport

References:

  • 1: Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson’s disease. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21. doi: 10.1124/jpet.111.187443. PubMed PMID: 22088953; PubMed Central PMCID: PMC3263969.
  • 2: Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology. 2015 Aug;95:121-9. doi: 10.1016/j.neuropharm.2015.02.023. PubMed PMID: 25749357; PubMed Central PMCID: PMC4466038.
  • 3: Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA. Neuropharmacology. 2015 Aug;95:121-9. doi: 10.1016/j.neuropharm.2015.02.023. Epub 2015 Mar 4.PMID: 25749357
  • 4.The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson’s disease. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21. doi: 10.1124/jpet.111.187443. Epub 2011 Nov 16. PMID: 22088953